Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn:
“The DESTINY-Breast09 trial may mark an important step forward in the first-line treatment of HER2-positive metastatic breast cancer.
At ASCO2025, I had the opportunity to present and discuss the interim PFS results comparing trastuzumab deruxtecan (T-DXd) plus pertuzumab with the long-standing THP regimen.
The data showed a near doubling of median PFS with T-DXd + P and consistent benefit across all subgroups—including both de novo and previously treated patients.
We also looked closely at safety signals and discussed what these findings could mean for sequencing strategies as T-DXd moves into earlier lines of therapy. With such promising early results, DESTINY-Breast09 has the potential to reshape the standard of care in this setting.
Watch the full video here.”
More posts featuring Sibylle Loibl.